Drug Profile
Research programme: cannabinoid-based therapeutics - InMed Pharmaceuticals
Alternative Names: CTI-091; Delta-9-tetrahydrocannabinol - InMed Pharmaceuticals; Dronabinol - InMed Pharmaceuticals; INM-405Latest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator Cannabis Technologies
- Developer InMed Pharmaceuticals; University of British Columbia
- Class Analgesics; Anti-inflammatories; Antirheumatics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators; Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
- No development reported Arthritis; Chronic obstructive pulmonary disease; Inflammation; Joint disorders; Musculoskeletal pain; Pain
Most Recent Events
- 19 Jun 2023 Early research in Unspecified in Canada (unspecified route) prior to June 2023 (InMed Pharmaceuticals pipeline, June 2023)
- 01 Apr 2022 InMed Pharmaceuticals has patents pending for cannabinoid analogues in North America
- 28 Apr 2019 No recent reports of development identified for preclinical development in Pain in Canada (Topical)